Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total O
Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NYS: PBYI) , a development stage biopharmaceutical company, announced that the underwriters for its public offering of 7,500,000 shares of its common stock at $16.00 per share have elected to exercise in full their option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 1,125,000 shares is expected to take place concurrently with the closing for the initial purchase of 7,500,000 shares on October 24, 2012, subject to customary closing conditions.
BofA Merrill Lynch and Leerink Swann LLC are acting as joint book-running managers for the offering. Stifel Nicolaus Weisel, Cowen and Company, and UBS Investment Bank are acting as co-managers for the offering.
A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission and declared effective. The offering of these securities will be made only by means of a written prospectus forming part of the effective registration statement relating to these securities. Copies of the prospectus for this offering may be obtained, when available, by contacting BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email: firstname.lastname@example.org or Leerink Swann LLC, One Federal Street, 37th Floor, Boston, MA 02110, Attn: Syndicate Department, phone: (800) 808-7525.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
Puma Biotechnology, Inc.
Mariann Ohanesian, +1-424-248-6500
KEYWORDS: United States North America California
The article Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.